Navigation Links
Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program
Date:4/28/2008

- Conference Call to Occur on Wednesday, April 30 at 2 p.m. Eastern -

FREMONT, Calif., April 28 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, will host a roundtable teleconference to address the need for improved detection of peripheral artery disease (PAD) and to provide information about the Company's PAD blood test, which is currently in late-stage development. The teleconference will take place on Wednesday, April 30 at 2 p.m. ET, and will feature as the keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at Stanford University, whose research forms the basis of Vermillion's PAD blood test.

In collaboration with Dr. Cooke and his research team at Stanford University, Vermillion has developed a novel panel of biomarkers in an effort to determine the risk of PAD through a simple blood test. Dr. Cooke, whose research focuses on preventive cardiology and vascular medicine, is the immediate past-president of the Society for Vascular Medicine and Biology. Dr. Cooke also serves on Vermillion's newly formed PAD clinical steering committee. In this role, he provides the Company with advice on additional studies to support registration of the PAD test with the U.S. Food and Drug Administration and to further potential market adoption.

Vermillion has an exclusive license agreement with Stanford to develop and commercialize the PAD biomarker panel.

About Peripheral Artery Disease (PAD)

PAD, a serious but often asymptomatic disorder affecting some eight to 12 million Americans, is caused by the buildup of fat and cholesterol, or plaque, in the peripheral arteries, disrupting normal blood flow. Left untreated, PAD more than doubles the risk of heart attack and stroke and increases the risk of amputation and death. There are treatments that can save the lives and limbs of these patients, once the disease is recognized.

Conference Call Information

To access the live conference call via phone, dial (888) 389-6569 from the United States and Canada or (706) 643-2819 internationally. The conference ID is 21381902. Please dial-in approximately ten minutes prior to the start of the call. Additionally, you may access the live and subsequently archived web cast of the conference call from the Investor Relations section of the Company's website at http://www.vermillion.com. Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

A telephone replay will be available beginning approximately two hours after the call through May 30, 2008 and may be accessed by dialing (800) 633-8284 from the United States and Canada or (+1 402) 977-9140 internationally. The replay passcode is 21381902. An archived replay of the web cast will be available until the next quarterly call.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at http://www.vermillion.com.

Forward Looking Statements This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize its PAD diagnostics products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize PAD diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop PAD diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its PAD diagnostic products; (5) uncertainty of market acceptance of its PAD diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.


'/>"/>
SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vermillion Announces Stockholder Approval of Reverse Stock Split
2. Vermillion to Host Teleconference and Webcast to Discuss Third Quarter 2007 Financial Results on November 12 at 4:30 pm Eastern Time
3. Vermillion, Inc. Announces Receipt of Notice of Noncompliance From Nasdaq
4. Privacy Experts Roundtable Report Will Highlight Privacy & Security Week
5. Genomic Health to Participate in Leerink Swann Roundtable Conference
6. BD to Present at the Leerink Swann Molecular Diagnostics Roundtable Conference
7. Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar
8. Lucian Leape Institute First Roundtable: A Resounding Success
9. OIG and HCCA Issue Government-Industry Roundtable Report
10. Lucian Leape Institute Announces First Roundtable
11. NFIB Joins AARP, Business Roundtable and SEIU in Divided We Fail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... MEDIA, Pa. , June 23, 2016 ... treatments in an outpatient dialysis facility.  Treatments are usually ... to 6 hours per visit, including travel time, equipment ... on a patient, but especially grueling for patients who ... residents of a skilled nursing and rehabilitation centers for ...
Breaking Medicine Technology: